Nicole Casasanta, Clinical Fellow, Medical Oncology at Yale New Haven Hospital, shared a post on LinkedIn:
“Impactful SABCS25 to wrap up 2025! The pace of oncology research and clinical trials is rapidly advancing.
- De-escalation trials are needed.
- Incorporation of ctDNA as a biomarker is showing promise in prognosis; further work is needed on clinical utility.
- Exciting advancements are being made in understanding mechanisms of therapy resistance.
- Multiple impactful clinical trials in HR+, HER2+, and TNBC were presented.
- Patient-reported outcomes are exceedingly important but may not tell the whole story.
- Partnering with patients should be at the center of care.”
More posts featuring Nicole Casasanta.
